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Abstract
Background: The development of expression-based gene signatures for predicting prognosis or class membership is a 
popular and challenging task. Besides their stringent validation, signatures need a functional interpretation and must be 
placed in a biological context. Popular tools such as Gene Set Enrichment have drawbacks because they are restricted to 
annotated genes and are unable to capture the information hidden in the signature’s non-annotated genes.
Methodology: We propose concepts to relate a signature with functional gene sets like pathways or Gene Ontology categories. 
The connection between single signature genes and a speciﬁ  c pathway is explored by hierarchical variable selection and 
gene association networks. The risk score derived from an individual patient’s signature is related to expression patterns of 
pathways and Gene Ontology categories. Global tests are useful for these tasks, and they adjust for other factors. GlobalAncova 
is used to explore the effect on gene expression in speciﬁ  c functional groups from the interaction of the score and selected 
mutations in the patient’s genome.
Results: We apply the proposed methods to an expression data set and a corresponding gene signature for predicting survival 
in Acute Myeloid Leukemia (AML). The example demonstrates strong relations between the signature and cancer-related 
pathways. The signature-based risk score was found to be associated with development-related biological processes.
Conclusions: Many authors interpret the functional aspects of a gene signature by linking signature genes to pathways or 
relevant functional gene groups. The method of gene set enrichment is preferred to annotating signature genes to speciﬁ  c 
Gene Ontology categories. The strategies proposed in this paper go beyond the restriction of annotation and deepen the 
insights into the biological mechanisms reﬂ  ected in the information given by a signature.
Introduction
Gene signatures are sets of genes along with an algorithm. Combined, the two allow for the discrimination 
between different biological entities (Kostka and Spang, 2008). While the focus of signatures is on 
discrimination, the functional aspect causing different phenotypes is hidden and not directly accessible 
from the signature’s information. This paper will introduce computational strategies for elucidating the 
functional context behind gene signatures.
In patient-oriented medicine it is of great importance to accurately classify patients into homogeneous 
diagnostic or prognostic subgroups and to supply therapies targeted to those subgroups (Schlenk et al. 
2008). Gene signatures derived by microarray technology play an important role in reﬁ  ning or 
supplementing existing diagnostic and prognostic factors such as staging systems (van de Vijver, 2002). 
But even if a signature is validated, proven to be accurate, and generalizable, there is still a long way 
to go before it is part of medical decision making. Wyatt and Altman (Wyatt and Altman, 1995) describe 
several features of prognostic models that facilitate their application in medical routines. A critical issue 
is whether the diagnostic/prognostic model can be interpreted in terms of the disease process.
In general, the biological interpretation of a gene signature follows a simple strategy: authors search 
for articles in which signature genes were described as relevant to the biological process under study. 330
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Interpreting different signatures that are developed 
for the same specific purpose from different 
research groups this way is impaired by the fact 
that the corresponding gene lists barely overlap. 
An example from colon cancer is instructive: three 
prognostic signatures show one single gene as 
common (Wang et al. 2004), (Barrier et al. 2006), 
and (Lin et al. 2007). The signatures seem to differ 
even if the same clinical population and the same 
endpoint are considered. Yu et al. (Yu et al. 2007) 
studied a similar example in breast cancer 
and found that the divergent gene signatures rep-
resent similar biological processes. An example 
from leukemia was discussed by Radmacher et al. 
(Radmacher et al. 2006). But discordance between 
signatures does not automatically imply deﬁ  cien-
cies in the derivation or differences with respect 
to their biological content.
Yu et al. (Yu et al. 2007) used the enrichment 
of signature genes in the Gene Ontology (GO) 
(Ashburner et al. 2000) to identify the functional 
implications of the signature. The association 
between the expression proﬁ  le of enriched gene 
sets and the patient prognosis was veriﬁ  ed using 
globaltest (Goeman et al. 2004). The authors even 
proposed the development of predictive signatures 
on the basis of gene sets that were shown to play 
an important role in the biology of the disease 
under study. This idea has also been discussed by 
Lottaz and Spang (Lottaz and Spang, 2005) as well 
as by Tai and Pan (Tai and Pan, 2007). Classiﬁ  ca-
tion strategies using annotated genes are dependent 
on the state of functional gene annotation and 
exclude a large part of information on gene expres-
sion that is available in signature genes that have 
not yet been integrated into a functional context. 
We aim for a signature interpretation that does not 
exclude signature genes not yet annotated.
We are interested in gene regulatory mecha-
nisms that are affected by the signature. The cor-
relation between the expression patterns of the 
signature and KEGG pathways (Kyoto Encyclo-
pedia of Genes and Genomes, http://www.genome.
jp/kegg/ (Kanehisa et al. 2006)) is explored by the 
GlobalAncova approach (Mansmann and Meister, 
2005; Hummel et al. 2008). The signature genes 
with the most inﬂ  uence on the pathway’s expres-
sion proﬁ  le are identiﬁ  ed by a hierarchical variable 
selection procedure (Meinshausen, 2008). Further-
more, we propose to study a gene association 
network (Schäfer and Strimmer, 2005) for the 
combined set of signature and pathway genes.
We illustrate the proposed strategies with a 
dataset of 163 patients suffering from acute 
myeloid leukemia (AML) (Metzeler et al. 2008). 
The dataset will be publicly available following 
publication of the original paper. We have devel-
oped a signature and a prognostic score to predict 
patient survival. Besides analyzing the role of 
individual signature genes, we use the prognostic 
score as a surrogate for the whole signature. The 
association between the prognostic score and rel-
evant pathways or Gene Ontology categories 
(Ashburner et al. 2000) is analyzed by GlobalAn-
cova (Mansmann and Meister, 2005; Hummel et al. 
2008) and globaltest (Goeman et al. 2004). Gene 
Ontology categories are scored by the focus level 
method (Goeman and Mansmann, 2008), which 
corrects for multiple testing while accounting for 
the special hierarchical structure of the GO. We 
also discuss the interaction between the signature 
and other relevant factors such as mutations.
Materials and Methods
The signature for predicting survival in AML was 
developed using the Supervised Principal Compo-
nents approach which selects genes whose expres-
sion patterns are correlated with survival and, 
based on those, generates a prognostic score (Bair 
and Tibshirani, 2004). Details about the signature 
development can be found in (Metzeler et al. 
2008). Figure 1 gives an overview over the analyses 
described in the following.
Hierarchical variable selection 
for the association between 
signature and pathways
The correlation between the expression proﬁ  les of 
the signature and the pathway (co-expression) is 
explored with GlobalAncova (Mansmann and 
Meister, 2005; Hummel et al. 2008). GlobalAn-
cova is based on a ﬂ  exible individual linear model 
for each gene of a speciﬁ  c set and summarizes the 
relevance of a regression variable in order to 
explain the gene expression in the given set. A 
single signature gene or a subgroup of genes can 
serve as the dependent variable(s) of interest. The 
goal is to identify the signature genes that affect 
the global expression of a speciﬁ  c pathway. This 
is a variable selection problem. To avoid a large 
number of false positive selections (Efron et al. 
2004), Meinshausen (Meinshausen, 2008) proposes 
a strategy that controls the errors in variable 331
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selection. The procedure renders a set of relevant 
signature genes that contains false positives with 
probability α (for a predeﬁ  ned error level α). 
Meinshausen’s hierarchical variable selection 
subsequently tests clusters of similar genes while 
keeping control of the family-wise error rate 
(FWER).
To this end, the signature is divided into 
nested groups via hierarchical clustering with a 
correlation-based distance measure. The root of 
the resulting binary tree corresponds to the whole 
signature, and its leaves are the single genes. 
Starting from the root, each cluster of signature 
genes is used as the set of regressors for the 
GlobalAncova test. Meinshausen adjusts each test 
for multiple testing adapted to the size of the 
respective cluster. Tests with large clusters of 
dependent variables are adjusted only weakly; 
whereas, single genes receive a Bonferroni-type 
adjustment. The algorithm proceeds as long as 
there are signiﬁ  cant test results until, in the end, 
the inﬂ  uences of single signature genes or small 
groups of genes on the expression proﬁ  le within 
the pathway are tested. We use a conservative error 
rate of α = 0.01.
Gene association networks 
for the association between 
signature and pathways
Alternatively, one may focus on gene-by-gene 
interactions in order to see which signature gene 
is related to which pathway gene. For this, we 
estimate gene dependency networks as proposed 
in Schäfer and Strimmer (Schäfer and Strimmer, 
2005). The resulting graphical model represents 
partial correlations, i.e. the correlations between 
two genes, while controlling for all the remaining 
genes. In order to avoid false positive edges in the 
network, an edge is only drawn if the respective 
genes have a partial correlation whose local false 
discovery rate (fdr) is smaller than 0.2. The net-
works are estimated using the R package GeneNet 
(Opgen-Rhein et al. 2006).
Association between expression-
based score and functional gene sets
GlobalAncova (Mansmann and Meister, 2005; 
Hummel et al. 2008) and globaltest (Goeman et al. 
2004) are used to test the association between the 
microarray-based prognostic score and the 
Figure 1. Schematic diagram of the analyses.
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expression proﬁ  le of a gene set while adjusting for 
other risk factors. GlobalAncova is also able to 
study the interaction between the prognostic score 
and a second risk factor (for example, a mutation). 
This enables researchers to determine whether the 
expression proﬁ  le within a pathway is regulated 
by the prognostic score differently for patients with 
versus without the speciﬁ  c mutation.
The proposed models are applied to pathways 
and Gene Ontology Biological Process (GOBP) 
categories (Ashburner et al. 2000). Since the 
GOBP consists of several thousand terms, an 
adjustment for multiple testing is required. We 
choose the focus level method (Goeman and 
Mansmann, 2008) that controls the FWER and 
accounts for the special hierarchical structure of 
the GO graph. The procedure is available in 
the Bioconductor packages globaltest and 
GlobalAncova. Pathway analysis is corrected by 
the Bonferroni method (Dudoit et al. 2003).
All analyses are done with the open source 
software R (The R Development Core Team 2007) 
(version 2.6.0) and Bioconductor (Gentleman et al. 
2004) (version 2.1).
Data
In order to illustrate this methods, we will discuss 
a data set of 163 adult AML patients with normal 
karyotype. Clinical data and Affymetrix HG-U133 
A + B microarrays are available for all patients. 
The mutation status of two prognostically relevant 
genes is also available: NPM1 (nucleophosmin 1, 
Entrez GeneID 4869) and FLT3 (fms-like tyrosine 
kinase 3, Entrez GeneID 2322) (Marcucci et al. 
2005). Details on the development and validation 
of the signature and the corresponding prognostic 
score can be found in (Metzeler et al. 2008).
The 44,754 measured Affymetrix probesets map 
to 18,481 unique gene symbols. All analyses are 
applied on a gene-basis instead of a probeset-basis. 
For each gene that maps to more than one probeset, 
one probeset is chosen to represent the gene’s 
expression value. We choose the probesets at ran-
dom since there is no “optimal” way for collapsing 
probesets to genes. Moreover, the probesets within 
the AML signature corresponding to the same gene, 
respectively, show high correlations.
We considered KEGG pathways (Kanehisa et al. 
2006), which generally represent known gene inter-
action networks. We use the information provided 
by the KEGG database about the association of genes 
to pathways for deﬁ  ning our pathway gene sets. The 
information about interactions between genes within 
the pathways is not used in our approaches. Fifteen 
genes of the 67 signature genes are annotated to 
KEGG pathways. Thirty-nine signature genes are 
annotated to terms of the Gene Ontology Biological 
Processes (Ashburner et al. 2000).
Results
Hierarchical variable selection 
for the association between 
signature and pathways
First, we wanted to know which signature genes 
inﬂ  uence the pathway for Acute Myeloid Leukemia 
(AML) (KEGG identiﬁ  er hsa05221). The AML 
oncogene RUNX1 (Entrez GeneID 861) belongs to 
both the signature and the AML pathway. The 
speciﬁ  c analysis for the gene FHL1 (known to be 
associated with a poor response to chemotherapy 
(Heuser et al. 2005), Entrez GeneID 2273) uses 
GlobalAncova. The expression of the FHL1 gene 
inﬂ  uences the expression proﬁ  le of the AML path-
way (p  0.0001). Figure 2 illustrates the estimated 
linear effects of FHL1 on the pathway genes, as 
calculated on a gene-wise basis. Several effects 
stay signiﬁ  cant after applying Bonferroni correction. 
The right side of Figure 2 is the GlobalAncova gene 
plot that shows gene-wise contributions to the 
global test statistic. Both plots support the strong 
correlation between FHL1 and the pathway.
The correlation between individual signature 
and pathway genes is shown in Figure 3. Most of 
the signature genes (55 of 67) are strongly associ-
ated with the expression pattern of the AML path-
way. The results show the inﬂ  uence on a speciﬁ  c 
pathway from genes not annotated to any pathway 
and genes annotated to other pathways. Most of 
the signature genes are positively correlated with 
important oncogenes in AML such as FLT3 or 
c-KIT (Entrez GeneID 3815).
A more sophisticated correlation structure is 
presented in Figure 4, where genes in the AML path-
way (original graph taken from http://www.genome.
jp/dbget-bin/www_bget?pathway+hsa05221) are 
marked with a red box when they correlate signiﬁ  -
cantly with signature genes (Bonferroni corrected 
for multiplicity). There is a dense interaction 
between the AML pathway and signature. A sys-
tematic search for signature genes that are 
co-regulated with genes in the acute myeloid 
pathway uses the hierarchical variable selection 333
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Figure 2. Relation between signature gene FHL1 and AML pathway. Left: Linear effects of signature gene FHL1 on the single genes within 
pathway ‘acute myeloid leukemia’ (hsa05221). Signiﬁ  cant gene-wise positive effects are indicated by thick black lines and corresponding 
gene names. Right: Corresponding GlobalAncova gene plot. The bar height indicates gene-wise contributions to the GlobalAncova statistic. 
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Figure 3. Heatmap of gene-wise correlations between signature genes and single genes of the AML pathway. Signature genes correspond 
to columns; genes within the pathway ‘acute myeloid leukemia’ (hsa05221) correspond to rows. Red spots indicate large positive correlation, 
green spots indicate large negative correlation, and dark spots stand for correlations around zero. Labels of signature genes are given in 
red for those genes that show a signiﬁ  cant inﬂ  uence on the AML pathway according to the hierarchical variable selection procedure. Affyme-
trix probeset identiﬁ  ers are used when no annotation to gene symbols exist.
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Figure 4. KEGG pathway ‘acute myeloid leukemia’ (hsa05221). Red boxes mark involved genes that correlate signiﬁ  cantly with at least one 
of the signature genes. Blue boxes mark genes that show a signiﬁ  cant partial correlation (in the gene association network) to at least one 
of the signature genes.
procedure of Meinshausen (Meinshausen, 2008). A 
similar analysis can be performed for all (200) 
KEGG pathways available in the corresponding R 
annotation package that contain at least one gene 
represented on the Affymetrix HG-U133 A + B 
genechip. Figure 5 shows which signature genes 
inﬂ  uence gene expression in 15 cancer-speciﬁ  c 
pathways. In Supplementary Figure 1 results are 
shown for the remaining 185 pathways.
Each signature gene is correlated with at 
least one of the pathways. On average, a gene is 
co-regulated with 122 of the 200 pathways. Only 
three pathways do not relate to any signature gene 
(‘Phenylpropanoid biosynthesis’ (hsa00940) 
‘Methane metabolism’ (hsa00680), ‘D-Arginine 
and D-ornithine metabolism’ (hsa00472)). On 
average, a pathway was inﬂ  uenced by 41 of the 
67 signature genes.
Gene association networks 
for the association between 
signature and pathways
A gene association network (Schäfer and Strimmer, 
2005) was estimated for the combined set of 
signature and ‘acute myeloid leukemia’ pathway 
genes. Figure 6 displays the observed connections 
and hides genes that were not connected. In the 
KEGG pathway graph (Fig. 4), the blue boxes 
highlight the elements that show a connection to 
the signature, according to the gene association 
network.
Association between expression-based 
score and functional gene sets
We look for gene groups whose expression 
profile is related to the prognostic score. 
Additionally, we want to control for the influence 
of the FLT3 mutation status. Two hundred 
KEGG pathways and 4,779 GOBP terms were 
scored. GlobalAncova and globaltest were used 
to establish the influence of the prognostic score 
adjusted for FLT3 mutation status. The FWER 
was controlled by the Bonferroni method in the 
pathway analysis and by the focus level proce-
dure (Goeman and Mansmann, 2008) in the GO 
analysis.
The results are presented in Table 1. From the 
200 pathways, GlobalAncova detected 168 path-
ways at the signiﬁ  cance level of 1% and globaltest 
detected 167, with an overlap of 166 pathways. In 
the GO analysis we detected 1781 (GlobalAncova) 
and 1751 (globaltest) terms with an overlap of 335
Functional interpretation of a gene signature
Bioinformatics and Biology Insights 2008:2
I
L
2
R
A
C
O
L
6
A
1
H
O
P
P
R
T
F
D
C
1
S
C
D
S
P
A
R
C
T
M
4
S
F
1
K
I
A
A
0
9
2
2
L
O
C
4
4
0
9
9
5
T
E
S
C
T
R
B
C
1
S
H
A
N
K
3
M
X
R
A
7
C
D
1
0
9
T
M
E
M
1
6
3
R
A
B
1
3
M
R
C
1
2
3
2
7
5
2
_
a
t
N
P
D
C
1
R
U
N
X
1
N
P
L
G
O
L
G
A
8
A
N
G
F
R
A
P
1
S
Y
N
J
2
F
H
L
1
2
4
1
1
3
3
_
a
t
B
I
C
Z
B
T
B
8
D
O
C
K
1
M
Y
O
5
C
C
9
o
r
f
5
8
W
B
P
5
H
I
S
T
1
H
2
A
D
K
I
A
A
0
1
2
5
A
R
M
C
X
1
L
I
M
S
3
L
G
A
L
S
3
R
A
B
3
4
A
B
I
2
S
O
C
S
2
F
A
M
9
2
A
1
C
1
0
o
r
f
1
2
8
T
C
F
4
M
S
I
2
B
C
A
T
1
T
S
C
2
2
D
1
M
A
S
T
4
P
H
G
D
H
S
L
C
2
5
A
3
7
F
A
M
3
0
A
B
C
L
1
1
A
G
P
S
M
1
H
B
G
2
L
A
P
T
M
4
B
2
2
7
9
4
3
_
a
t
C
O
L
2
4
A
1
G
P
R
5
6
A
T
P
8
B
2
S
C
H
I
P
1
A
C
P
6
R
P
L
3
5
A
D
A
P
K
1
2
3
0
7
9
5
_
a
t
2
3
9
2
3
7
_
a
t
M
A
P
1
A
G
U
C
Y
1
A
3
M
A
R
V
E
L
D
1
Renal cell carcinoma
Endometrial cancer
Glioma
Pancreatic cancer
Non−small cell lung cancer
Colorectal cancer
Prostate cancer
Thyroid cancer
Chronic myeloid leukemia
Basal cell carcinoma
Hematopoietic cell lineage
Bladder cancer
Small cell lung cancer
Acute myeloid leukemia
Melanoma
Figure 5. Result of hierarchical variable selection for 15 cancer-speciﬁ  c KEGG pathways. Rows indicate pathways; columns show the 
67 signature genes. Squares are dark gray rather than light gray if there is a signiﬁ  cant inﬂ  uence of the respective signature gene on the 
respective pathway (adjusted p-value = 0.0067).
1730, also with a level of 1%. We were interested 
in functional groups in which the effect of the 
prognostic score is different between the groups 
deﬁ  ned by FLT3 mutation status. The pathway 
analysis did not yield any signiﬁ  cant ﬁ  nding. 
When testing all GOBP terms for an interaction 
effect, a subgraph of 10 terms was detected 
(Fig. 7). The most speciﬁ  c terms are ‘notochord 
development’ (GO:0030903) and ‘embryonic 
organ development’ (GO:0048568). Table 2 shows 
the genes annotated to GO:0048568. Figure 8 
shows the differential co-regulation between the 
prognostic score and individual genes within this 
GO term.
Discussion
We provide strategies to elucidate the biological 
context of gene signatures. Though the method-
ologies used are not new, we apply them in a novel 
context. The work was motivated by the observation 
that a large part of the signature genes are not 
annotated to pathways or Gene Ontology terms. 
This excludes large parts of the signature from 336
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Figure 6. A gene association network that shows relations between signature and AML pathway genes. Blue nodes correspond to genes in 
the pathway ‘acute myeloid leukemia’ (hsa05221), and red nodes correspond to genes in the prognostic signature. Only edges correspond-
ing to partial correlations considerably different from 0 (with fdr adjusted p-values  0.2) are displayed. Correspondingly, only genes that 
are connected by an edge to another gene are shown. Affymetrix probeset identiﬁ  ers are used when no annotation to gene symbols exist.
Meister, 2005; Hummel et al. 2008) or globaltest 
(Goeman et al. 2004), or by estimating gene asso-
ciation networks (Schäfer and Strimmer, 2005).
The idea of relating signatures with functional 
gene sets was already proposed by Yu et al. 
(Yu et al. 2007). The authors used gene set enrich-
ment analysis in order to detect gene sets that 
contain (relatively) large numbers of signature 
genes. The concept provided in this paper is dif-
ferent from the concept of Yu et al. (Yu et al. 2007). 
Gene set enrichment detects biological processes 
that best represent the signature; whereas, we try 
to ﬁ  nd gene sets that interact with it. Gene set 
enrichment concentrates on gene names and 
ignores the observed expression values. It also 
Gene Set Enrichment analyses and restricts the 
elucidation of a signature’s cellular context.
Besides a focused analysis for the single com-
ponents of a signature, we also study co-regulation 
of the prognostic score with pathways or Gene 
Ontology Biological Process categories. The prog-
nostic score offers a ‘summary’ of the relevant gene 
expression information included in all the signature 
genes.
The methods are illustrated on a prognostic 
signature for AML patients with normal karyotype. 
We propose the exploration of the interaction in 
expression profiles between a signature and 
functional pathways of interest by either testing 
linear relations with GlobalAncova (Mansmann and 337
Functional interpretation of a gene signature
Bioinformatics and Biology Insights 2008:2
1
2 3
4 5
67
8
9
10
ID Terms
1   GO:0008150  biological_process
2   GO:0032502  developmental process
3   GO:0032501  multicellular organismal process
4   GO:0007275  multicellular organismal development
5   GO:0048856  anatomical stucture development
6   GO:0009790  embryonic development
9   GO:0048568  embryonic organ development
7   GO:0048731  system development
8   GO:0048513  organ development
10   GO:0030903  notochord development
genes
12224
2774
2892
1949
1772
223
1454
1021
17
3
Figure 7. Result from GO scoring with the focus level procedure. GOBP terms are shown whose expression patterns are signiﬁ  cantly affected 
by the interaction between expression-based prognostic score and FLT3 mutation status.
studies the randomness of membership in groups 
(is there an over-representation of statisticians in 
our institute compared to the statisticians working 
within the medical college?). Gene set enrichment 
does not answer questions such as whether the 
activity in one group is relevant to the activities 
observed in another group.
Furthermore, gene set enrichment restricts the 
analysis to the annotated genes of a signature. Our 
approach extends the analysis and allows the study 
of relationships between sets of not yet annotated 
genes and annotated gene groups. Only 15 genes 
of the signature are annotated to KEGG pathways. 
Thirty-nine of the 67 signature genes cannot 
be annotated to terms of the GO Biological 
Processes.
The KEGG pathway ‘acute myeloid leukemia’ 
is used as a speciﬁ  c example. Though only one 
gene in the signature (RUNX1) belongs to this 
pathway, many other signature genes show a strong 
correlation to the expression of several genes 
within the pathway. In particular, large parts of the 
signature correlate with well-known AML onco-
genes such as FLT3 or c-Kit. Some of the signature 
genes related to the AML pathway by the 
GlobalAncova-based approach and by the gene 
association networks are reported to play a role in 
other types of tumors, e.g. BCAT1 (Entrez GeneID 
586) (Rodríguez et al. 2003) and SCHIP1 (Entrez 
GeneID 29970) (Scoles, 2008).
The activity of 55 of the 67 signature genes can 
be associated (hierarchical variable selection) to 
the AML pathway. Twenty-four of the 55 genes are 
not annotated to another KEGG pathway. SHIP1 
is one of these 24 genes.
The results of the hierarchical variable selection 
are not directly comparable to the results given by 
the graphical model of the interaction networks. 
First, the graphical model exhibits fewer associations 
Table 1. Result of pathway and GO analysis when 
testing the prognostic score adjusted by FLT3 status. 
The numbers of significant findings obtained by 
GlobalAncova and globaltest after FWER correction at 
a level of 1% are shown. Additionally, the numbers of 
gene sets found by both global test approaches and 
total numbers of gene sets are given.
KEGG GOBP
GlobalAncova 168 1781
globaltest 167 1751
Overlap 166 1730
Total 200 4779338
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Table 2. Genes in the Biological Process GO category ‘embryonic organ development’ (GO:0048568). The 
expression proﬁ  le of this GO category is affected by the interaction between FLT3 status and expression-based 
prognostic score (see Fig. 7). Genes in the also signiﬁ  cant offspring term ‘notochord development’ (GO:0030903) 
are written in bold.
Symbol Name
MYST3 MYST histone acetyltransferase (monocytic leukemia) 3
SH2B3 SH2B adaptor protein 3
MED1 mediator complex subunit 1
RARG retinoic acid receptor, gamma
TINAG tubulointerstitial nephritis antigen
ROR2 receptor tyrosine kinase-like orphan receptor 2
FOXF1 forkhead box F1
FOXF2 forkhead box F2
FOXL2 forkhead box L2
SHH sonic hedgehog homolog (Drosophila)
SHOX2 short stature homeobox 2
MLL myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
OVOL2 ovo-like 2 (Drosophila)
GLI3 GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome)
GLI1 glioma-associated oncogene homolog 1 (zinc ﬁ  nger protein)
GLI2 GLI-Kruppel family member GLI2
NOG noggin
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Figure 8. Gene-wise linear effects of the expression-based prognostic score on GOBP term ‘GO:0048568: embryonic organ development’. 
The term corresponds to node 9 in Figure 7. Signiﬁ  cant (after simple Bonferroni correction) effects are indicated by red lines for positive 
effects and green lines for negative effects. The corresponding gene names are shown. Effects are calculated separately for patients with 
(right) and without (left) mutation in FLT3.339
Functional interpretation of a gene signature
Bioinformatics and Biology Insights 2008:2
between signature and pathway. Second, there were 
edges present in the estimated network; whereas, 
the corresponding signature genes did not show a 
signiﬁ  cant inﬂ  uence on the AML pathway in the 
hierarchical approach.
Those differences do not have straightforward 
explanations. They are due to the different concepts 
of Pearson and partial correlation. A pair of genes, 
A and B, can have a detectable partial correlation, 
while the correlation of A or B to some other genes 
may be stronger than the correlation between A and 
B themselves. Within the AML pathway graph 
provided by KEGG (Fig. 4), the blue boxes high-
light the parts that correspond to interactions 
between signature and pathway as given by the 
gene association network in Figure 6. There is an 
overlap between the red and blue boxes in Figure 4. 
So despite their differences, the hierarchical 
approach and the graphical model do show some 
convergence. The latter approach led to a sparser 
connectivity between signature and pathway.
We use pathways as lists of genes in our 
approach. The form and direction of interrelation-
ships are not captured by our methods. Further-
more, the relationships depicted in the KEGG 
representation are of a different nature than those 
estimated by gene interaction networks. For 
example, the connections between genes within 
the AML pathway detected by the graphical model 
(Fig. 6) do no correspond directly to the connec-
tions known from laboratory research (Fig. 4).
The comparability of results from GlobalAn-
cova and globaltest has been discussed in the lit-
erature (Mansmann and Meister, 2005; Liu et al. 
2007). From the large amount of signiﬁ  cant ﬁ  nd-
ings we concluded that patients with different score 
values were quite variable with respect to many 
kinds of biological processes and pathways. This 
underlines the relevance of the signature and the 
corresponding score.
The analysis also reveals the interaction of the 
FLT3 status of a patient and the prognostic score 
in speciﬁ  c functional gene groups. The GOBP 
group GO:0048568 ‘embryonic organ develop-
ment’ shows that the expression proﬁ  les in wild-
type patients are inﬂ  uenced in a different way than 
for patients with the FLT3 mutation.
The integration of gene signatures into a bio-
logical (functional, cellular) context is the starting 
point for basic research in molecular medicine, in 
order to elucidate the relationship between diag-
nostic or prognostic differences and differences in 
the disease process. The methods presented in this 
paper aim to broaden the scope of available strate-
gies. They map out information that is helpful in 
guiding the design of new experiments on model 
organisms. They also produce information that is 
useful for improving annotation activities.
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Figure S1. Result of hierarchical variable selection for 185 (non-cancer-speciﬁ  c) KEGG pathways. Rows indicate pathways; columns show 
the 67 signature genes. Squares are dark gray rather than light gray if there is a signiﬁ  cant inﬂ  uence of that signature gene on that pathway 
(adjusted p-value = 0.0067). A legend with pathway IDs and names is given in Supplementary Table 1. 
Table S1. Legend for Supplementary Figure S1.